Skip to main content
S&P 5007,794.26-0.32%DOW51,182.13-0.66%NASDAQ27,470.58-0.47%BTC$83,404.00-2.68%ETH$2,565.50-4.97%GOLD$4,136.50-1.21%OIL$88.91-0.59%
Smart Investors Daily
SID Premium
CG

NASDAQ · CGTX

Cognition Therapeutics, Inc.

Healthcare · Biotechnology

$0.94

Up+$0.01 (+0.67%)

Updated Oct 7, 2026, 4:48 PM

SID Score

3.3/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
119.2M
P/E ratio
-3.13
Dividend yield
0.00%
52-week range
$0.55 – $1.76
Volume
330.51K
Avg. volume
1.86M

Price performance · CGTX

CGTX price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 6, 2026

CGTX closed at $0.94 after 21 trading sessions, down 6.93% for the selected period.

Last close
$0.94
Period change
-6.93%
Period low
$0.89
Period high
$1.06
Daily close
View OHLC price history
CGTX OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 6, 2026$0.94$0.9598$0.9259$0.94330.51K
Oct 5, 2026$0.9441$0.9699$0.9192$0.9381331.79K
Oct 2, 2026$0.921$0.9299$0.9011$0.9251302.4K
Oct 1, 2026$0.98$0.9876$0.89$0.8912792.16K
Sep 30, 2026$0.9797$0.9838$0.9599$0.96386.2K
Sep 29, 2026$0.96$0.9799$0.9327$0.9544526.51K
Sep 28, 2026$0.9289$0.9599$0.92$0.9384200.59K
Sep 25, 2026$0.98$0.98$0.9335$0.9365540.06K
Sep 24, 2026$0.9674$0.9674$0.93$0.9508266.92K
Sep 23, 2026$1.00$1.01$0.95$0.95563.7K
Sep 22, 2026$1.03$1.03$0.9813$0.9813332.34K
Sep 21, 2026$1.05$1.075$1.00$1.00769.83K
Sep 18, 2026$1.06$1.07$1.04$1.04336.7K
Sep 17, 2026$1.04$1.08$1.025$1.06615.87K
Sep 16, 2026$1.04$1.07$1.01$1.02531.7K
Sep 15, 2026$1.00$1.045$0.9812$1.035627.29K
Sep 14, 2026$0.9872$1.03$0.9703$1.01231.38K
Sep 11, 2026$0.9769$1.00$0.9701$0.9828218.02K
Sep 10, 2026$0.99$1.005$0.97$0.9797300.39K
Sep 9, 2026$1.01$1.03$0.9864$0.99473.92K
Sep 8, 2026$1.02$1.04$1.00$1.01261.51K

Latest CGTX news

The latest Smart Investors Daily articles mentioning CGTX.

Stock researchCompany · Overview

CGTX research

Overview

Company profile and research snapshot.

Company profile

Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
CGTX recent ratings
DateFirmRatingTarget
Mar 27, 2026Chardan CapitalBuy—
Dec 4, 2025HC Wainwright & Co.Buy—
Nov 21, 2025B. Riley SecuritiesBuy—
Nov 19, 2025HC Wainwright & Co.Buy—
Aug 8, 2025Chardan CapitalBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 29, 2026

Cognition Therapeutics Schedules a Type C Meeting with FDA to Align on Endpoints for Phase 3 Trial of Zervimesine (CT1812) in DLB

October 20th Meeting with the Division of Neurology Expected to Define Endpoint for Phase 3PURCHASE, N.Y., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical-stage company developing product candidates that treat neurodegenerative disorders, (the “Company” or “Cognition”), announced that a Type C meeting with the U.S. Food and Drug Administration (FDA) Division of Neurology has been scheduled for October 20, 2026. The objective

Yahoo · Sep 8, 2026

Cognition Therapeutics to Present at H.C. Wainwright Global Investment Conference

PURCHASE, N.Y., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that the Company’s president and CEO, Lisa Ricciardi intends to present at the H.C. Wainwright 28th Annual Global Investment Conference on Tuesday, September 15, 2026 at 2:30 p.m. Eastern Time. During her presentation, Ms. Ricciardi will discuss progress on the Company’s development of zervimesine for Alzheimer

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By